Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06408259 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Celgene.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT06408259: Recruiting Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Celgene.
NCT06408259 is a Phase 3 study of Multiple Sclerosis (Relapsing Remitting) that is actively recruiting participants, run by Celgene. The registered enrollment target is 194 participants, below the 556-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06408259, a Phase 3 study of Multiple Sclerosis (Relapsing Remitting), is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ozanimod
- DRUG Fingolimod
Study Locations (20)
California
- Local Institution - 0114 - Loma Linda
- University of California Davis Health - Sacramento
Illinois
- Local Institution - 0093 - Chicago
- University of Chicago Medical Center - Chicago
New Jersey
- Local Institution - 0131 - New Brunswick
- Local Institution - 0132 - Teaneck
Lombardy
- Ospedale San Raffaele - Milan
- Local Institution - 0081 - Milan
Florida
- University of South Florida - Tampa
Kentucky
- Local Institution - 0047 - Louisville
Ohio
- Local Institution - 0091 - Cincinnati
Oregon
- Local Institution - 0092 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2036-07-13 |
| Phase | Phase 3 |
What NCT06408259 shows while recruiting
NCT06408259 is an interventional study that assigns participants to a tested intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, below the 556-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06408259 names 20 study sites across 16 states, led by California, Illinois, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06408259 about?
NCT06408259 is a clinical study titled "Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis". The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
What is the current status of trial NCT06408259?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2025-04-08. Estimated completion is 2036-07-13.
What conditions does trial NCT06408259 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT06408259?
The interventions under investigation include: Placebo (OTHER), Ozanimod (DRUG), Fingolimod (DRUG).
Who is sponsoring clinical trial NCT06408259?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06408259 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06408259's enrollment target sits among peer trials
194 9th of 29 higher than 21 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
COMPLETED · Phase 3
-
ACTH for Fatigue in Multiple Sclerosis Patients
COMPLETED · Phase 3
-
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
COMPLETED · Phase 3
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
- NCT05351424 · 194 participants · NA
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI